These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11912383)

  • 1. Early onset prostate cancer: predictors of clinical grade.
    Kotsis SV; Spencer SL; Peyser PA; Montie JE; Cooney KA
    J Urol; 2002 Apr; 167(4):1659-63. PubMed ID: 11912383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Family history of prostate cancer and obesity in relation to high-grade disease and extraprostatic extension in young men with prostate cancer.
    Rohrmann S; Roberts WW; Walsh PC; Platz EA
    Prostate; 2003 May; 55(2):140-6. PubMed ID: 12661039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease.
    Dall'era MA; Hosang N; Konety B; Cowan JE; Carroll PR
    J Urol; 2009 Apr; 181(4):1622-7; discussion 1627. PubMed ID: 19230923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hereditary aspects of prostate cancer.
    McLellan DL; Norman RW
    CMAJ; 1995 Oct; 153(7):895-900. PubMed ID: 7553490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
    Loeb S; Nadler RB; Roehl KA; Antenor JA; Catalona WJ
    J Urol; 2007 May; 177(5):1745-8. PubMed ID: 17437803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.
    Pruthi RS; Swords K; Schultz H; Carson CC; Wallen EM
    J Urol; 2009 Feb; 181(2):574-7; discussion 578. PubMed ID: 19084847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate brachytherapy: a descriptive analysis from CaPSURE.
    Lee WR; Sharkey J; Cowan JE; DuChane J; Carroll PR;
    Brachytherapy; 2007; 6(2):123-8. PubMed ID: 17434105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is race a positive predictor of cancer on repeat prostate biopsy?
    Yanke BV; Salzhauer EW; Colon I
    J Urol; 2006 Sep; 176(3):1114-7. PubMed ID: 16890704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer.
    Krejcarek SC; Chen MH; Renshaw AA; Loffredo M; Sussman B; D'Amico AV
    Urology; 2007 Mar; 69(3):515-9. PubMed ID: 17382156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Percent Gleason grade 4/5 as prognostic factor in prostate cancer diagnosed at transurethral resection.
    Egevad L; Granfors T; Karlberg L; Bergh A; Stattin P
    J Urol; 2002 Aug; 168(2):509-13. PubMed ID: 12131299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The independent impact of extended pattern biopsy on prostate cancer stage migration.
    Master VA; Chi T; Simko JP; Weinberg V; Carroll PR
    J Urol; 2005 Nov; 174(5):1789-93; discussion 1793. PubMed ID: 16217288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher frequency of familial clustering of prostate cancer in French-Canadian men.
    Filion E; Taussky D; Bahary JP; Maugard CM
    J Urol; 2007 Oct; 178(4 Pt 1):1265-9; discussion 1270. PubMed ID: 17698103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic features in men who died of prostate cancer.
    Thompson KE; Hernández J; Canby-Hagino ED; Troyer D; Thompson IM
    J Urol; 2005 Aug; 174(2):553-6; discussion 556. PubMed ID: 16006890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial aspects of prostate cancer: a case control study.
    Keetch DW; Rice JP; Suarez BK; Catalona WJ
    J Urol; 1995 Dec; 154(6):2100-2. PubMed ID: 7500468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer.
    Moussa AS; Li J; Soriano M; Klein EA; Dong F; Jones JS
    BJU Int; 2009 Jan; 103(1):43-8. PubMed ID: 18782303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age.
    Sweat SD; Bergstralh EJ; Slezak J; Blute ML; Zincke H
    J Urol; 2002 Aug; 168(2):525-9. PubMed ID: 12131302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
    Thompson IM; Pauler Ankerst D; Chi C; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
    J Clin Oncol; 2007 Jul; 25(21):3076-81. PubMed ID: 17634486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer.
    Punglia RS; Cullen J; McLeod DG; Chen Y; D'Amico AV
    Cancer; 2007 Nov; 110(9):1973-8. PubMed ID: 17886252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological characteristics of prostate cancer in elderly men.
    Delongchamps NB; Wang CY; Chandan V; Jones RF; Threatte G; Jumbelic M; de la Roza G; Haas GP
    J Urol; 2009 Sep; 182(3):927-30. PubMed ID: 19616228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials.
    Nanda A; Chen MH; Renshaw AA; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1419-23. PubMed ID: 19131185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.